logo-loader
viewScancell Holdings PLC

Scancell Holdings lays groundwork for pivotal year

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D

Scancell Holdings PLC -
ts lead drug, SCIB-1, developed from its ImmunoBody technology, has recently entered a phase II clinical trial here in the UK

Scancell Holdings PLC (LON:SCLP) described the 12 months to the end of April as a “busy and productive year” – one in which the building blocks for the clinical development of its two lead drugs were laid.

Alongside its prelims, the company confirmed manufacturing of its Modi-1 vaccine for solid tumours, developed from the Moditope platform, is progressing well. As a result, it expects to be able to begin clinical trials in the first half of next year.

Its lead drug, SCIB-1, developed from its ImmunoBody technology, has recently entered a phase II clinical trial here in the UK.

The study will initially assess the safety and efficacy of the treatment in 25 people with a metastatic form of skin cancer, melanoma. SCIB-1 will be used in harness with Merck’s checkpoint inhibitor Keytruda.

Scancell remains in discussions with regulators over the minutiae of a parallel clinical assessment in the US.

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D.

As is common with drug developers at this formative stage of their development, the group was loss-making. The deficit for the year was £5.6mln as development expenditure grew to £4.15mln.

Quick facts: Scancell Holdings PLC

Price: 5.05 GBX

LSE:SCLP
Market: LSE
Market Cap: £23.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates. A placing and subscription at 12 pence a share will account for...

on 18/4/18

2 min read